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Transplant recipients have an increased risk of developing cancer in comparison with the general population. We present here data
on cancer development in transplanted subjects who received organs from donors whose DNA was previously examined for the
genomic insertion of Simian Virus 40 (SV40). Active follow-up of 387 recipients of solid organs donated by 134 donors, not clinically
affected by cancer, was performed through the National Transplant Center (NTC). The average length of follow-up after transplant
was 6717219 days (range 0–1085 days). Out of 134 proposed donors, 120 were utilised for organ donation. Of these, 12 (10%)
were classified as positive for SV40 genomic insertion. None of the 41 recipients of organs from SV40 positive donors developed a
tumour during the follow-up. In all, 11 recipients of organs given by SV40 negative donors developed a tumour (cancer incidence:
0.015 per year). In conclusion, cancer rates observed in our study are comparable to what reported by the literature in transplanted
patients. Recipients of solid organs from SV40 positive donors do not have an increased risk of cancer after transplant. The role of
SV40 in carcinogenesis in transplanted patients may be minimal.
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One of the major consequences of solid organ transplantation is
the high incidence of cancer after transplant. Transplant recipients
have a three- to four-fold increased risk of developing cancer in
comparison with the general population (Pedotti et al, 2003), at
least for kidney and heart (Cardillo et al, 2001) transplants. Cancer
occurrence in these patients has been attributed to the type and
dose of immunosuppressive regimen, the presence of cancer in the
donor’s organ and to viral infections.
Simian virus 40 (SV40), a member of the polyomavirus family
together with BK and JC, has been shown to be oncogenic in
rodents, and has been detected in human tumours and tissues at
variable frequencies. A systematic review of the literature indicates
that the frequency of SV40 genomic infection in healthy subjects
varies from 6 to 11% (Paracchini et al, 2006). The virus was
inadvertently transmitted to humans through the Poliovirus
vaccine in US between 1955 and 1963 (Butel and Lednicky,
1999a). However, epidemiological studies do not indicate an
increased incidence of cancer associated with such contamination
(Strickler et al, 2003). We have reported (Paracchini et al, 2005)
that the prevalence of SV40 genomic infection in healthy subjects
is not associated with year of birth, thus suggesting that factors
other than polio vaccine could be responsible for the infection.
The role of SV40 sequences in human tumorigenesis remains
controversial; polyomavirus infections have been associated with
mesothelioma, CNS tumours and non-Hodgkin lymphomas
(Bergsagel et al, 1992; Martini et al, 1996; Galateau-Salle et al,
1998; Klein et al, 2002; Vilchez et al, 2002a; Carbone et al, 2003;
MacKenzie et al, 2003), even though at present there is no clear
consensus on the prevalence of SV40 positivity in human tumours
tissues (Klein et al, 2002; Carbone et al, 2003; Vilchez et al, 2003;
Paracchini et al, 2006).
Several studies (Shah et al, 1974; Butel et al, 1999b; Li et al,
2002) and reviews (Kwak et al, 2002; Vilchez et al, 2002b; Vilchez
et al, 2003; Kazory and Ducloux, 2003) have tackled the issue of the
presence of polyomaviruses (BK, JC and SV40) in solid organ
transplant recipients, reporting prevalence of infection between
18% (Shah et al, 1974) and 40% (Butel et al, 1999b). However,
no epidemiological study has been conducted so far on cancer
development in subjects who received organs from SV40 positive
donors. The finding of an increase frequency of cancer in
recipients from positive donors would add strength to the
hypothesis of a role of SV40 in cancer aetiopathogenesis. We
present here data on cancer development in transplanted subject
who received organs from donors whose DNA was previously
examined for the genomic insertion of SV40 (Paracchini et al,
2005).
MATERIALS AND METHODS
In all, 134 solid organ donors were identified through a previous
study conducted between 2002 and 2004 within the North Italian
Transplant Reference Center of the Policlinico Hospital of Milano,
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sItaly, with the aim of assessing the prevalence of SV40 genomic
infection (Paracchini et al, 2005). None of the donors were
clinically affected by cancer at the time of organ donation
(Paracchini et al, 2005). Briefly, DNA was isolated from blood
samples from organ donors, and PCR reactions were performed in
order to determine the presence of SV40 sequences in the donors’
DNA. Negative and positive controls were included in all sets of
reactions. The pBRSV (ATCC 45019, from G Khoury) plasmid,
containing the entire genome of the reference strain SV40–776,
was used as the positive control in PCR amplification. Special
precautions were taken in order to avoid laboratory contamination
with SV40 sequences. The analysis was repeated in a blind fashion,
in order to confirm the results. DNA from samples that were
positive for SV40 by PCR were sequenced twice in both directions
using specific primers according to the manufacturer’s protocol
(ABI PRISM
s Big Dye TM Terminator Cycle Sequencing Ready
Reaction Kit, Applied Biosystems, Foster City, CA, USA).
The organs deriving from these donors were distributed to
different transplant centers in Italy (Bergamo, Bologna, Brescia,
Genova, Milan, Modena, Padova, Palermo, Pavia, Pisa, Roma,
Torino, Treviso, Udine, Varese, Vicenza, Verona). Informed
consent for organ donation and evaluation of organ safety, as
required by Italian law, was obtained from family members at the
time of organ donation. The Hospital Ethical Committee approved
the program of solid organ donation.
The follow-up of the recipients was performed through the
National Transplant Center (NTC), part of the Superior Institute of
Health. This Institute was created in March 2000 with the purpose
of coordinating the activity of all the centres operating in the
transplant system, and to assure the monitoring of transplant
quality. The NTC conducts a yearly follow-up of the vital status of
all the solid organ transplanted subjects in Italy, and among the
other information, collects data on cancer incidence.
Statistical analysis
Arithmetic means and s.d. of the demographic variables were
calculated. Patients’ survival was calculated using the actuarial
method (Kaplan–Meier survival analysis). Each patient in the
cohort was included in the analysis and counted from the date of
transplant to the date of cancer development, or death or loss at
follow-up.
The expected number of cancer cases in subjects who received
organs from SV40 positive donors was calculated by applying
cancer incidence rates observed among recipients of organs from
SV40 negative donors. The Monte Carlo w
2 was used to test if a
significant difference existed between observed and expected
number of cancer cases. All the statistical analyses were performed
using the SAS statistical package (version 8, SAS Institute Inc.,
Cary, NC, USA).
RESULTS
Out of 134 proposed donors, 120 were actually utilised for organ
donation. Of these, 12 (10%) were subsequently classified as
positive for SV40 genomic insertion (Paracchini et al, 2005). None
of the positive samples showed sequence homology with either
JCV or BKV sequences.
The 120 utilised donors were Caucasians, 56.7% males, with an
average age at organ donation of 48716 years (range 21–78
years), and gave 408 solid organs (kidney, heart, pancreas, liver
and lung) to 387 different recipients (Table 1). The average length
of follow-up after transplant was 6717219 days (range 0–1085
days). Out of 387 transplant recipients, we obtained follow-up
information on 364 subjects (94.1%). The missing information
refer to 21 subjects from a transplant centre which preferred not to
furnish follow-up data, and to two subjects whose organs were
given to the European transplant organisation, and therefore
where not followed-up by the NTC. Out of the 364 transplanted
subjects, 11 developed cancer (3.0%): five after kidney transplant
(three male subjects and two female subjects), five after liver
transplant (four male subjects and one female subjects), and one
after heart transplant (a male subject). The average actuarial
incidence of cancer was 0.015 per year.
The 12 subjects subsequently identified as SV40 positive donors
donated 43 organs to 41 recipients (Table 2). None of these
recipients developed cancer during the follow-up period (average
follow-up 6717266 days).













Kidney 115 218 216 0.53 2 double kidneys
Liver 104 113 113 0.92 2 combined with
kidney
Heart 50 50 50 1.00
Pancreas 14 14 14 1.00 13 combined with
kidney
Lung 13 13 9 1.44 4 double lungs
Total 120 408 387 0.31 21
Table 2 Distribution of the organs deriving from donors tested for SV40 genomic insertion
Type of organ No. of organs Recipients Donors Follow-up (days) mean7s.d. No. of cancers
Donors positive for SV40
Kidney 24 23 12 7587184 0/23
Liver 13 13 12 5777279 0/13
Heart 5 5 5 472772 0/5
Pancreas 1 1 1 535 0/1
Total 43 41 12 6717266 0/41
Donors negative for SV40
Kidney 194 193 103 7087198 5/193 (2.6%)
a
Liver 100 98 92 6827232 5/100 (5.0%)
b
Heart 45 45 45 4487193 1/45 (2.2%)
c
Pancreas 13 13 13 7157137 0/13
Lung 13 8 7 796775 0/9
Total 365 346 108 6677219 11/346 (3.2%)
aThree male subjects with skin (n¼2), and Kaposi; two female subjects with uterus and kidney.
bFour male subjects with liver recurrence (n¼3), and lung; one female subject
with liver recurrence.
cMale with lung cancer.
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sThe remaining 108 donors who were subsequently identified as
SV40 negative gave 365 organs to 346 recipients (Table 2). In all 11
of these recipients developed cancer during the follow-up period
(6677219 days). The 11 patients who developed cancer received
organs from 11 different donors (Table 2). These donors also
donated other 35 organs, but none of the recipients developed
cancer.
The expected number of cases among recipient of organs from
positive donors was 1 per year, for a total of two expected cases
during the whole follow-up period; however, no subject who




Simian Virus 40 DNA infection has been detected in several but not
all human tumour types (Bergsagel et al,1 9 9 2 ;M a r t i n iet al, 1996;
Galateau-Salle et al,1 9 9 8 ;K l e i net al, 2002; Vilchez et al, 2002a;
Carbone et al, 2003; MacKenzie et al, 2003). The lack of consistency
of the results may reflect the type of tumours examined, the age of
the patients, the analytical methods used to detect genomic SV40
infection, or possible laboratory contamination (Butel and Lednicky,
1999a; Lopez-Rios et al, 2004; Paracchini et al, 2006). The summary
of published studies on the association between SV40 and cancer
(Butel and Lednicky, 1999a) suggests that, even if the virus may be
an important co-factor in cancer development, its aetiological role is
not yet proven, and the time needed for completing the
carcinogenesis process is not known for SV40.
A further consideration is that SV40 DNA has been found in
tumour cells, but it has also been detected in peripheral blood of
otherwise healthy subjects (Paracchini et al, 2006). Although SV40
has been shown to be tumorigenic in animal models (Eddy et al,
1962), no appropriate comparable model has been developed in
human subjects to study SV40 carcinogenicity. We are using a
unique approach, in which the SV40 genomic status of the donors
before transplant is known, and is correlated with the follow-up of
the recipient for cancer development. As the information on SV40
genomic infection status of the donors was available a priori,i tw a s
possible to know which recipient was directly exposed to the
infection after transplant.
Only a few studies have examined SV40 infection in transplanted
patients (Shah et al, 1974; Butel et al, 1999b; Mylonakis et al, 2001),
but nobody has studied cancer development in relation to SV40
infection in these patients. Among the strengths of this study is the
fact that the population of transplanted patients is part of a highly
controlled system of follow-up, set up at a national level, which
allowed an almost complete follow-up of the subjects (over 94%).
Moreover, all the donors were clinically free of cancer at the time
of donation, and they were tested for the presence of SV40.
One of the limitations of the study could be the short follow-up
period. In a previous study conducted in Italy on the incidence of
cancer after kidney transplant, the average time to cancer
development after transplant was 1200 days (Pedotti et al, 2003),
while the average follow-up in this study is 670 days. However,
Kaposi sarcoma (KS) and post transplantation lymphoproliferative
disorders (PTLDs) are more likely generated by patient viral
reactivation or viral transmission from the donor to recipients
(Barete et al, 2000), and such tumours require less time to develop
than solid organ tumours. Viral infection from Epstein–Barr virus
(EBV) or HHV8, for example, was associated with PTLDs or KS,
with incidences that were maximal during the first year (Gulley
et al, 2003; Snanoudj et al, 2003; Faull et al, 2005) after transplant.
However, since the latent period for SV40 carcinogenesis is not
known, the length of follow-up necessary to assess a risk of cancer
related to SV40 genomic infection in these patients remains a
theoretical question. Repeated yearly follow-ups of these patients
are ongoing.
This study examined the presence of genomic insertion of SV40
in transplant recipients’ DNA, in order to avoid the cross reactivity
to antibodies to the common human JC and BK viruses (Carter
et al, 2003; Knowles et al, 2003), therefore, we have no data on
carcinogenicity related to these viruses. Testing for the presence of
genomic insertion of these viruses and cancer development could
be valuable in future studies.
Cancer rates observed in our study are comparable to that
reported in the literature in transplanted patients (Pedotti et al,
2003). The application of the expected cancer incidence rates
(observed among recipients of organs from SV40 negative donors)
to the subjects who received organs from SV40 positive donors
should yield an expected number of cases around 1 per year, for a
total of two expected cases during the whole follow-up period. Our
data show that no subject who received organs from SV40 positive
donors developed a tumour, thus the results show less than the
expected incidence. Although this result does not indicate any
protective effect of SV40, it is certainly consistent with a lack of
carcinogenic activity of the virus in organ-transplanted subjects.
As the genomic presence of SV40 in the recipients was not
tested, it could be possible that some of the subjects who developed
a tumour were SV40 positive independently from the donor status.
However, even if some of the recipients were SV40 positive, the
fact that they did not develop any tumour during the follow-up
strengthens our results. Therefore, knowing the SV40 infective
status of the recipients would not decrease the strength of the
result observed in the recipients of organs from positive donors,
none of whom developed cancer. In conclusion, SV40 positive
donors do not seem to increase the risk of cancer after
transplantation.
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